Exchange: NASDAQ·Updated 07:30 PM EST

KRYS News

News
all
press releases
Krystal Biotech Analyst Says Stock Weakness 'Overblown'
Krystal Biotech beats Q3 earnings, but trial delays send shares lower. Analysts call the market drop overblown and highlight a potential buying opportunity.read more...
Benzinga
Krystal Biotech Analyst Says Stock Weakness 'Overblown'
Krystal Biotech beats Q3 earnings, but trial delays send shares lower. Analysts call the market drop overblown and highlight a potential buying opportunity.read more...
Benzinga
More News
Krystal Biotech (KRYS) delivered earnings and revenue surprises of +11.41% and +2.16%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Krystal Biotech (NASDAQ:KRYS) reported third-quarter financial results on Monday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.read more...
Benzinga
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 31.65% on an annualized basis producing an average annual return of 42.52%. Currently, Krystal Biotech has a market capitalization ofread more...
Benzinga
Krystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.
Zacks
Krystal Biotech reports clinical updates for KB113, showing over an 80% reduction in basal cell carcinoma lesions in Gorlin syndrome.read more...
Benzinga
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.16% on an annualized basis producing an average annual return of 44.36%. Currently, Krystal Biotech has a market capitalization ofread more...
Benzinga
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.48% on an annualized basis producing an average annual return of 43.76%. Currently, Krystal Biotech has a market capitalization ofread more...
Benzinga

Advertisement|Remove ads.